Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Bayer bought China-based Dihon Pharmaceutical Group, which specializes in traditional Chinese medicine consumer goods.
The drugmaker says the voluntary measure was out of an abundance of caution.
The agency says is it time to update the onerous decades-old review process.
Bloomberg reports that Teva has sparked interest as a takeover target.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.
The CEO told Leerink analysts the pharma business needs better margins, not unfettered R&D budgets.
Driven by a number of high-profile buys in 2013, pharma saw a return to investment through acquisition after a 2012 dip.
The new manufacturing site will be its first in Asia.
A panel is meeting February 10 to discuss revoking the OTC status of some medications.
The suit stalls Eli Lilly's biosimilar version of insulin glargine.
168 employees will be pink-slipped this quarter.
Amgen 2013 revenues increased by 17% from 2012 to $18.7 billion, the company reported, but it faces headwinds in 2014 for older meds.
Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.
Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.
The news follows company statements that China is not business friendly.
Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.
The company will be beefing up support of Sandoz, its generics division.
The latest IMS report shows that 50% of the top 50 pharma companies are not on social media. Executive Director Murray Aitken tells MM&M it is to pharma's detriment.
Analyst Seamus Fernandez, of Leerink Partners, says the drugmaker is set to be a considerable immuno-oncology and respiratory presence.
Herve Hoppenot changed jobs overnight.
The company bought rights to a Phase-II drug for recurrent migraine headaches.
The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.
An insider says Merck may be up for trading its OTC business for Novartis's animal health business, but the benefits for either side may be better on paper.
Erez Vigodman will be Teva's president and CEO as of February 11.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.